Device Trial Radar · NCT07796061
Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2031
Study completion Dec 2032
Sponsor
- Lead sponsor
- Children's National Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Focused Ultrasound Foundation
- First posted
- Aug 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 3 years, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label phase 1 safety and feasibility study evaluating a novel combination therapy for Diffuse Midline Glioma (DMG), an aggressive brain tumor with a very poor prognosis - an average one-year overall survival. This study combines blood-brain barrier (BBB) disruption (BBBD) using low-intensity focused ultrasound (LIFU) and microbubble treatment, and intravenous infusion of autologous, tumor multi-antigen associated specific cytotoxic T lymphocyte (TAA-T) therapy. The TAA-T cell investigational product in this protocol is manufactured to target Preferentially Expressed Antigen of Melanoma (PRAME), Wilms Tumor 1 (WT1), and survivin.
Conditions
- DMG
- DIPG
Interventions
TAA-T CellBiological
Intravenous tumor associated antigen specific T cell (TAA-T) infusion.
BBB DisruptionDevice
BBB disruption using the Exablate 4000 Type 2 System with DEFINITY microbubbles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EvaluationTime frame: Within 28 days from last treatment
- Feasibility evaluationTime frame: Within 28 days from last treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's National Hospital
Washington D.C., District of Columbia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.